WO2018021874A1 - Functional sanitary napkin - Google Patents

Functional sanitary napkin Download PDF

Info

Publication number
WO2018021874A1
WO2018021874A1 PCT/KR2017/008163 KR2017008163W WO2018021874A1 WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1 KR 2017008163 W KR2017008163 W KR 2017008163W WO 2018021874 A1 WO2018021874 A1 WO 2018021874A1
Authority
WO
WIPO (PCT)
Prior art keywords
accession
culture
sanitary napkin
nite
lactobacillus plantarum
Prior art date
Application number
PCT/KR2017/008163
Other languages
French (fr)
Korean (ko)
Inventor
김기태
Original Assignee
바이오제닉스코리아 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2016-0096967 priority Critical
Priority to KR20160096967 priority
Application filed by 바이오제닉스코리아 주식회사 filed Critical 바이오제닉스코리아 주식회사
Publication of WO2018021874A1 publication Critical patent/WO2018021874A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47Sanitary towels, incontinence pads or napkins
    • A61F13/472Sanitary towels, incontinence pads or napkins specially adapted for female use
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84Accessories, not otherwise provided for, for absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms

Abstract

The present invention discloses a functional sanitary napkin which is impregnated with a culture of lactic acid bacteria, such as Lactobacillus plantarum nF1, exhibiting antibacterial, anti-inflammatory, and anti-allergic activities, thereby having the effect of preventing pathogens such as bacteria from infecting the human body and secretions such as menstrual blood from causing skin irritation, skin eczema, and skin inflammation.

Description

Functional sanitary napkin

The present invention relates to a functional sanitary napkin, and more particularly, to a functional sanitary napkin having antibacterial, anti-inflammatory and anti-allergic properties, which can prevent infection, skin irritation, and eczema by pathogens.

The endometrium of a woman of childbearing age is periodically proliferated by hormones to prepare for implantation of the embryo. If the pregnancy does not occur, the endometrium is spontaneously dropped and this phenomenon is called menstruation or menstruation. Fertility refers to the period during which the egg can ovulate and become pregnant. It refers to the period from the beginning of menarche to menopause. The average menopause age is about 13 years old and the average menopause age is about 50 years old. Menstrual cycles can be divided into follicular and luteal phases, and ovulation occurs during the transition from follicular phases to luteal phases. In the follicle, the secretion of female hormone (estrogen) increases in the ovary, which stops menstruation and the lining of the uterus proliferates and begins to thicken. At the same time, when the egg matures in one ovary and the menstrual cycle is 28 days, ovulation occurs about 14 days before the start of menstruation. After ovulation, luteal hormone (progesterone) secretion increases in the ovaries, which helps prepare for endometrial implantation. If you are not pregnant, the endometrium will fall off on day 28. Normal menstrual cycles are usually between 21 and 35 days (28 days on average), lasting 3 to 7 days at intervals between the start of two consecutive menstruation periods. Looks normal.

The sanitary napkin is used to prevent leakage of menstrual blood and secretion during the menstrual period, as shown in Figure 1, the sanitary napkin is generally to prevent the leakage of the internal sheet 100, such as menstrual blood, and menstrual blood In order to have the outer sheet 300 and the absorbent member 200 positioned between the inner sheet 100 and the outer sheet 300 to absorb the menstrual blood, etc., and to absorb the menstrual blood. The outer sheet 300 may be provided with an adhesive means such as an adhesive material.

However, sanitary napkins may cause skin irritation, skin eczema, and skin irritation due to secretions such as menstrual blood, and during menstruation, mental and physical resistance is weakened. Therefore, human infections such as skin infections and vaginal infections are caused by bacterial growth such as pathogens. May cause problems.

The present invention confirms that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 disclosed in Korean Patent Registration No. 10-1583018 and Korean Patent Application Publication No. 2014-0140387 have anti-allergic and anti-inflammatory activity as well as antibacterial activity. A functional sanitary napkin is disclosed that can prevent human infection by bacteria such as pathogens and prevent skin irritation.

An object of the present invention is to provide a functional sanitary napkin that can prevent infection and skin irritation caused by pathogens.

Other and specific objects of the present invention will be presented below.

The functional sanitary napkin of the present invention comprises (i) an inner sheet and an outer sheet, and (ii) an absorbent member interposed therebetween, wherein the inner sheet and / or absorbent member is Lactobacillus plantarum. It is characterized by impregnating a lactic acid bacteria culture such as nF1 or a solution containing the same.

By having such a structure, that is, lactic acid bacteria culture such as Lactobacillus plantarum nF1 is impregnated into the inner sheet and / or absorbent member, the functional sanitary napkin of the present invention exhibits anti-inflammatory, anti-allergic, as well as antibacterial, Due to such antimicrobial properties, it has the effect of preventing human infection from bacteria such as pathogens, and also has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.

As can be seen in the experimental example below, lactic acid bacteria cultures such as Lactobacillus plantarum nF1, Bacillus subtilis , Staphylococcus aureus (except for some microorganisms of some cultures) Staphylococcus aureus ), Staphylococcus mutans ( Strptococcus) mutans ), Escherichia coli ) and Gardnerella vaginalis , which have an overall antimicrobial activity and produce nitric oxide (NO) in macrophages, a major cell in the inflammatory response stimulated with the inflammatory substance lipopolysacharide (LPS). In addition to showing inhibitory activity, it exhibits degranulation inhibitory activity in the rat cell line RBL-2H3 (rat basophilic leukemia), which is a major cell of the allergic reaction, activated with IgE and antigen (DNP-BSA), which are initiating factors of the allergic reaction.

The gardnerella pannalis is an anaerobic bacterium known as a major causative agent of bacterial vaginosis found in more than 98% of women with bacterial vaginosis (Korean Journal of Obstetrics and Gynecology 36 (6): 837-46, 1993). Bacterial vaginosis caused by is caused to increase the pH in the vagina to 5.0 or more, exhibits peculiar odors, pruritus and other symptoms, and is characterized by increased vaginal discharge (Am J Obstet Gynecol. 158 (4): 819-). 28, 1988).

In addition, NO, which is excessively produced by iNOS (induced NOS) during the inflammatory reaction, reacts with superoxide to form peroxynitrite, which acts as a powerful oxidant and damages cells, thereby causing inflammation and cancer. Has been reported to be involved in a variety of pathological processes including (Gupta SC et al., Exp Biol Med., 236: 658-671, 2011; Riehemann et al., FEBS Lett., 442: 89-94, 1999; Stame et al. , Science, 258: 1898-1902, 1992), substances that inhibit NO production have been proposed as anti-inflammatory candidates (Karin M. et al., Cold Spring Harb Perspect Biol., 1, pp 1-14, 2009) . In addition, mast cells, which are the major mediators of allergic reactions, contain beta-hexosaminidase in addition to histamine, and beta-hexosaminidase is released together with histamine when mast cells degranulate. Beta-hexosaminidase is known as an indicator for assessing degranulation inhibitory activity, antihistamine activity and anti-allergic activity of mast cells (Immunol., 123: 1445-1450, 1970); J Korean Soc Appl Biol Chem. 48 (4): 315-321, 2005).

Therefore, the experimental example below shows that lactic acid bacteria cultures such as Lactobacillus plantarum nF1 prevent bacterial vaginosis caused by infections such as Gardnerella pannalis through antibacterial activity, anti-inflammatory activity and anti-allergic activity. It can be said that it can alleviate skin inflammation.

As used herein, "lactic acid bacteria" refers to Lactobacillus plantarum nF1 (Accession No. NITE P-1462), Lactobacillus plantarum SNK12 (Accession No .: NITE P-1445), Lactobacillus plantarum KH3 (Accession No. NITE AP) -1476), Enterococcus faecalis KH2 (Accession No. NITE P-1444), and / or Lactobacillus brevis (Accession No. FERP BP-4693) ("Labre"), which are lactobacillus products manufactured by an independent Japanese corporation. It is a microorganism entrusted to the National Institute of Technology and Evaluation (NITE; International Patent Organism Depositary, IPOD) of the Evaluation Technology Infrastructure Organization. See 2014-0140387. These patent documents are all considered part of this specification.

In the present specification, "lactic acid bacteria culture" is obtained by inoculating and culturing lactic acid bacteria with a suitable medium in which lactic acid bacteria can grow, such as MRS Broth. The culture itself and its culture are concentrated under reduced pressure and / or lyophilized. Processed into liquid or powder form, the culture itself or the processed product thereof having a lower alcohol having 1 to 4 carbon atoms such as water, methanol, ethanol, butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate Suspensions or solutions suspended or dissolved in butyl acetate, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, the culture Meaning extracting itself or its processed product with the solvents listed above, and processing the extract into liquid or powder form by concentration under reduced pressure and / or lyophilization. . In the case where a suspension, a solution, an extract, or the like is used for impregnation, it is preferable to remove the dispersion medium or the solvent after the impregnation in a manner known in the art such as a hot air drying method. In order to stabilize the impregnation of the lactic acid bacteria culture and to prevent the dispersion medium or the solvent may be toxic to the human body such as skin irritation. For this reason, preferred dispersion mediums or solvents are water, ethanol or a mixed solvent thereof.

The functional sanitary napkin of the present invention may further include an auxiliary absorbing member, and when the auxiliary absorbing member is further included, an end portion may be further formed in the endothelial sheet so that the auxiliary absorbing member may be detachably inserted.

The functional sanitary napkin of the present invention is an inner sheet, an absorbent member, an outer sheet, and an optional absorbent member which is an optional absorbent member, which is a component of a conventional sanitary napkin, and their materials and configurations are known in the art, and related details are as follows. See embodiments of.

As described above, according to the present invention, a functional sanitary napkin impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1 exhibiting antibacterial activity, anti-inflammatory activity, anti-allergic activity and the like can be provided.

The functional sanitary napkin of the present invention is impregnated with a lactic acid bacteria culture such as Lactobacillus plantarum nF1, which exhibits antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., and thus has an effect of preventing human infection from bacteria such as pathogens. It has the effect of preventing skin irritation, skin eczema, and skin inflammation caused by secretions such as menstrual blood.

1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention.

2 is an exploded perspective view of the sanitary napkin according to the preferred embodiment of the present invention.

3 is a perspective view of a sanitary napkin according to another preferred embodiment of the present invention.

Hereinafter, exemplary embodiments will be described with reference to the accompanying drawings. However, the scope of the present invention is not limited to these examples.

1 is a perspective view of a sanitary napkin according to a preferred embodiment of the present invention, Figure 2 is an exploded perspective view of the sanitary napkin according to a preferred embodiment of the present invention.

In the present invention, the antibacterial sanitary napkin is largely composed of an inner sheet 100 and an outer sheet 300 and an absorbing member 200 disposed therebetween.

The inner sheet 100 has a material and structure through which secretion, such as menstrual blood, can pass, and may be specifically composed of one or more layers of fabrics or nonwoven fabrics. The fibers constituting the woven or nonwoven fabric can be used both synthetic fibers and natural fibers without particular limitation, if synthetic fibers, nylon, polyvinyl alcohol (PVA) fibers, polyester fibers, polyacrylic fibers, polyamide fibers, polyurethane Fibers, polyacrylonitrile fibers, polypropylene fibers, polyethylene fibers and the like can all be used without limitation, and if natural fibers, cotton fibers, seed fibers such as Coier, leaf vein fibers such as manila hemp and sisal hemp, flax , Bast fibers such as ramie grass, hemp, wool fibers such as wool, goat wool, silk fibers such as gaze dog, and night sleep dog can be used without limitation. Preferably, in order to minimize the irritation to the human body when using a fabric made of natural fibers, such as cotton fabrics.

The inner sheet 100 is a member in contact with the human body may be caused skin irritation, skin eczema, skin inflammation, etc. by secretions such as menstrual blood absorbed in the inner sheet 100 or penetrating the inner sheet 100, including pathogens Since various bacteria can proliferate, in order to prevent such skin irritation and suppress the growth of various bacteria, Lactobacillus has been confirmed antimicrobial activity, anti-inflammatory activity, anti-allergic activity, etc., as confirmed in the experimental example below Lactobacillus cultures such as plantarum nF1, its extracts, its concentrates, its dilutions, or its suspensions or solutions using a dispersion medium or a solvent as water or ethanol are impregnated into the inner sheet 100 for antibacterial function, You can have anti-inflammatory activity, anti-allergy, etc.

At this time, the impregnation may be made by immersing the inner sheet 100 in a diluent of a lactic acid bacterium culture such as Lactobacillus plantarum nF1 at room temperature, preferably for at least 12 hours, more preferably at least 24 hours. After soaking, the lactic acid bacteria cultures such as Lactobacillus plantarum nF1, which are impregnated, are stabilized and hot air dried at a temperature ranging from 40 ° C. to 50 ° C., for example, to remove solvents that may cause irritation or toxicity to the skin. It may be desirable to.

Meanwhile, various natural materials have been proposed in the art to alleviate skin irritation. Such natural materials include plant extracts having anti-inflammatory activity, anti-allergic activity, or both, specifically, Styrax japonica extract, Chloranthus japonicus ) extract, Podocarpus macrophyllus extract, Distylium racemosom extract, Rhododendron mucronulatum , Empetrum nigrum extract, Marsilea quadrifolia extract, Potentilla discolor extract, Gleichenia japonica extract, Cimicifuga acerina extract, Citrus sunki rind extract, Sceptridium ternatum extract and Korthalsella japonica extract are among such plant extracts. When impregnating these natural materials with lactic acid bacteria cultures such as Lactobacillus plantarum nF1 to the inner sheet 100, or impregnated alone, imparting skin irritation, skin trouble relieving effect, or enhancing or enhancing such effects. Can be designed.

When the extract is impregnated, endothelial sheet by immersing the endothelial sheet 100 in these natural product extracts at a constant time, such as 12 hours or 24 hours or more at room temperature, using an extract in the extract state with or without filtration. Functionality such as skin irritation relief can be imparted to (100). In addition to water and ethanol, the extraction solvent which may have skin irritation may be a solvent remaining in the endothelial sheet 100 when impregnated, and the residual solvent may cause skin irritation, so that the impregnated inner sheet 100 may be hot air dried. Drying is carried out in a manner known in the art to remove residual solvents, or when using an extract obtained with an extraction solvent other than water and ethanol, it is concentrated in the art after extraction, freeze drying, vacuum drying, hot air drying, spray drying, etc. It is also possible to avoid the skin irritation problem caused by the extraction solvent by removing the extraction solvent in a manner known in the present invention to obtain a powdered extract and dissolving the powdered extract in water or ethanol, especially ethanol.

In the functional sanitary napkin of the present invention, the absorbent member 200 is to absorb secretions such as menstrual blood, so that the absorbency and water retention should be excellent, so that the absorbent member 200 may consider cotton fiber or wool, goat's wool, etc. It can be made of the hair wool fiber, etc. in the form of cotton and the composition of the nonwoven fabric and the like. Preferably, the content may be a polymer absorbent such as sodium polyacrylate, which has been conventionally used in sanitary napkins. Sodium polyacrylate is a material known in the art to have an absorption ability to absorb about 200 times its weight.

Since the absorbing member 200 is a member for absorbing secretions such as menstrual blood, bacteria such as pathogens may proliferate. Therefore, in order to suppress this, it is preferable to impregnate the culture of lactic acid bacteria such as Lactobacillus plantarum nF1, such as the antibacterial activity is confirmed, such as the inner sheet 100 to have an antibacterial function.

In the functional sanitary napkin of the present invention, the outer sheet 300 is located on the outside of the absorbent member 200. Since the outer sheet 300 is a member in contact with the underwear without touching the skin, it should be able to prevent the leakage of secretion such as menstrual blood. It is made of a waterproof material such as polyethylene film. In addition, the outer surface of the outer sheet 300 can be attached to and fixed to the underwear by forming an adhesive member with an adhesive and release paper.

In the functional sanitary napkin of the present invention, the adsorption member 200 is finally placed between the inner sheet 100 and the outer sheet 300, and the periphery of the inner sheet 100 and the outer sheet 300 is stitched, ultrasonically fused or heated. It is made by bonding by fusion.

In addition, the functional sanitary napkin of the present invention may further comprise an auxiliary adsorption member 400 for further use in the case of a large amount of secretion, such as menstrual blood, depending on the woman as shown in FIG.

Similarly to the adsorption member 200, the auxiliary adsorption member 400 may be made of cotton fibers, wool fibers such as wool, goat wool, or the like in the form of cotton, or a polymer absorbent such as sodium polyacrylate. Like the adsorption member 200, the outer shell may be made of a nonwoven fabric or the like.

When the functional sanitary napkin of the present invention further includes the auxiliary adsorption member 400, the inner sheet 100 may be inserted to detach the auxiliary adsorption member 100 by forming a cutout 101.

In addition, it may be preferable to impregnate the lactic acid bacteria culture such as Lactobacillus plantarum nF1 so that the auxiliary adsorption member 400 also has antibacterial properties.

As described above, the functional sanitary napkin of the present invention has been described based on the inner sheet 100, the absorbent member 200, and the outer sheet 300, which are basic components, but the functional sanitary napkin of the present invention is the inner sheet 100 and / or absorbent. The member 200 is impregnated with a culture of lactic acid bacteria such as Lactobacillus plantarum nF1 to have antimicrobial activity, anti-inflammatory activity, anti-allergy, and the like. It is to be understood that added and modified sanitary napkins are also included in the scope of the present invention.

< Experimental Example > Lactobacillus Planta Room nF1  Antimicrobial, Anti-inflammatory and Anti-allergic Activities of Cultures

< Experimental Example  1> Lactobacillus Planta Room nF1  Antimicrobial activity test

Experimental Example 1-1 Lactobacillus Plantarum Preparation of nF1 Culture, etc.

Lactobacillus was inoculated at MRS (DeMan, Rogosa, and Sharpe) broth (Difco Lactobacilli MRS Broth, Japan Becton, Dickinson & Co.) at an initial cell concentration of 1 × 10 4 cfu / mL, and Lactobacillus plantarum nF1 (Accession No. NITE P-1462) ("nF1"), Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445) ("SNK12"), Lactobacillus plantarum KH3 (Accession Number NITE AP-1476) ("KH3" ) At 32 ° C., 37 ° C. for Enterococcus faecalis KH2 (Accession No. NITE P-1444) (“KH2”), and 31 to 32 for Lactobacillus brevis (Accession No. FERP BP-4693) (“Labre”). C., Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848) (“CF4”) was incubated at 30 ° C. for 2 days.

The culture was sterilized at 121 ° C. for 20 minutes using a sterilizer, concentrated under reduced pressure and lyophilized, and used for experiments while refrigerated.

<Experimental Example 1-2> Antimicrobial activity experiment by plate medium diffusion method

Antimicrobial activity was measured by plate medium diffusion method (Food. Chem. Toxicol. 40 (4): 535-543, 2002). The disk to be used for the experiment was dissolved in ethanol at a concentration of 1 mg / ml of the sample (culture of <Experimental Example 1-1>), and then slowly absorbed the sample solution into the disk (Whatman No. 5), and then completely removed the solvent. Prepared by evaporation. The prepared disk was adhered to the plate medium plated with each test bacteria and incubated at the incubation temperature of the following [Table 1], and then the size (mm) of growth zones (clear zone) formed around the disk was measured. The results are shown in [Table 2].

Strain Culture condition Bacillus subtilis KCTC 1021 Nutrient media, 30 ℃, Aerobic Staphylococcus aureus KCTC 1927 Nutrient media, 37 ℃, Aerobic Strptococcus mutans KCTC 3300 Nutrient media, 37 ℃, Aerobic Esherichia coli KCTC 1039 Nutrient media, 37 ℃, Aerobic Gardnerella vaginalis KCTC 5096 Nutrient media, 37 ℃, Anaerobic

Size of growth inhibiting ring (mm) Strain nF1 SNK12 KH3 KH2 Labre CF4 B. subtilis - 6.50 10.50 8.25 4.25 - S. aureus 8.50 8.0 6.50 - 8.0 5.0 S. mutans 11.0 9.25 6.50 8.50 4.50 8.25 E. coli 4.0 5.0 8.0 8.25 9.0 - G. vaginalis 14.50 9.25 5.0 7.25 - 6.0 *-: No antimicrobial activity

The results of Table 2 show that the lactic acid bacteria culture of <Experimental Example 1-1> was the most effective against the microorganisms of the microorganisms except for some cases, such as the lactic acid bacteria nF1 culture did not show antimicrobial activity against B. subtilis . It showed antimicrobial activity.

< Experimental Example  2> Anti-inflammatory activity test-NO assay

Anti-inflammatory activity was evaluated using a cell model in which RAW264.7 cells, a mouse macrophage line, were stimulated with Lipopolysacharide (LPS). Specifically, the mouse macrophage cells were dispensed in a 48 well plate with a cell number of 5 × 10 4 cells / well and incubated for 24 hours at 37 ° C. and 5% CO 2 . 100 μg / ml sample and 1 μg / ml LPS were co-treated and incubated for 24 hours. After incubation, 50 μl of cell culture supernatant and 50 μl of Griess reagent [1% (w / v) sulfanilamide, 0.1% (w / v) naphylethylenediamine in 2.5% (v / v) phosphoric acid] were mixed and reacted at room temperature for 10 minutes. After measuring the absorbance at 540nm was measured the NO production inhibitory ability compared to the control by ELISA measurement. The amount of NO produced was compared with sodium nitrite (NaNO 2 ) as standard.

The results are shown in Table 3 below.

NO production inhibitory activity (%) and cell survival rate (%) Strain nF1 SNK12 KH3 KH2 Labre CF4 NO production inhibitory ability 38.43 ± 7.64 28.56 ± 3.27 56.32 ± 5.27 43.54 ± 4.86 62.28 ± 5.62 48.60 ± 5.38 Cell viability 94.28 ± 5.27 102.48 ± 4.45 106.32 ± 3.29 98.27 ± 4.49 102.60 ± 11.08 97.52 ± 6.24

The results of Table 2 show a difference in NO production inhibitory activity, but shows that the lactic acid bacteria culture of Experimental Example 1-1 generally showed NO production inhibitory activity against LPS-stimulated mouse macrophage lines.

Cell viability was measured by the MTT method. Specifically, the remaining medium in the 48 well plate was removed, and 100 μl of serum free medium containing 10% of 5 mg / ml MTT solution was added to each well in 37 ° C. and 5% CO 2 incubator, followed by reaction for 2 hours. Removed and dissolved DMSO in 100μl / well for 15 minutes in the shaker and measured the absorbance at 540nm using ELlSA reader to determine the cell viability. The results are shown in Table 3 together.

As confirmed in [Table 3], it can be seen that the lactic acid bacteria cultures of <Experimental Example 1-1> do not exhibit cytotoxicity in particular, and the NO production suppression result is not due to cytotoxicity. have.

< Experimental Example  3> Anti-allergy  Activity experiment-β- hexosaminidase  assay

Anti-allergic activity was assessed by β-hexosaminidase assay.

To evaluate the β-hexosaminidase assay, a rat basophilic leukemia cell line RBL-2H3 cell line was dispensed into 2 wells at 24 × plates at 2 × 10 5 cells / well and treated with 0.5 μg / ml mouse monoclonal IgE at 37 ° C., 5%. Cells were sensitized by incubating overnight in CO 2 conditions. The sensitized cells were washed twice with siraganian buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 40 mM NaOH, pH 7.2) and 160 μl PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 0.4 mM MgCl 2 , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) was added and incubated at 37 ° C. for 10 minutes. Thereafter, 100 µg / ml of the sample was added to react for 20 minutes, and 20 µl of DNP-HSA (Dinitrophenyl-Human Serum Albumin, 1 µg / ml) was treated with an antigen and incubated at 37 ° C. for 10 minutes to remove degranulated particles. Induced. Next, 20 µl of the supernatant of the reactants was put into a 96 well plate, and 20 µm of substrate 1 mM P-nitrophenyl-acetyl-β-D-glucosamide was added and reacted at 37 ° C. for 1 hour. A stop solution (0.1 M NaHCO 3 , 0.1 M Na 2 CO 3 ) was added thereto, and the reaction was terminated. The absorbance was measured using an ELISA reader at a wavelength of 405 nm. The results are shown in [Table 4] as a percentage compared to the sample untreated group.

Degranulation inhibitory activity (β-hexosaminidase free inhibitory activity) (%) Strain nF1 SNK12 KH3 KH2 Labre CF4 Degranulation inhibitory activity 42.57 ± 4.69 52.26 ± 9.36 46.28 ± 11.82 48.48 ± 12.92 36.80 ± 5.27 64.28 ± 8.29

The results of Table 4 show a difference in activity, but shows that the lactic acid bacteria culture of <Experimental Example 1-1> showed anti-granular inhibitory activity as a whole and had anti-allergic activity.

[Description of the code]

100: inner sheet

200: absorbing member

300: outer sheet

400: auxiliary absorbing member

Claims (5)

  1. (i) inner and outer sheets with periphery joined together;
    (ii) including an absorbent member interposed therebetween,
    Functional sanitary napkins, characterized in that any one of the inner sheet and the absorbent member is impregnated with any one culture selected from the culture of lactic acid bacteria (a) to (f) or a solution containing the culture:
    (a) Lactobacillus plantarum nF1 (Accession No. NITE P-1462),
    (b) Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445),
    (c) Lactobacillus plantarum KH3 (Accession No. NITE AP-1476),
    (d) Enterococcus faecalis KH2 (Accession No. NITE P-1444),
    (e) Lactobacillus brevis (Accession No. FERP BP-4693), and
    (f) Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848).
  2. The method of claim 1,
    The lactic acid bacteria culture is a functional sanitary napkin, characterized in that the Lactobacillus plantarum nF1 (Accession Number NITE P-1462) culture.
  3. The method of claim 1,
    The functional sanitary napkin further comprises an auxiliary absorbing member, wherein the inner sheet is a functional sanitary napkin, characterized in that the incision is formed to be inserted into the secondary absorbent member detachably.
  4. The method of claim 3,
    Functional auxiliary sanitary napkin is characterized in that the auxiliary absorbing member is impregnated with any one culture selected from the culture of lactic acid bacteria (a) to (f) or a solution containing the culture:
    (a) Lactobacillus plantarum nF1 (Accession No. NITE P-1462),
    (b) Lactobacillus plantarum SNK12 (Accession Number: NITE P-1445),
    (c) Lactobacillus plantarum KH3 (Accession No. NITE AP-1476),
    (d) Enterococcus faecalis KH2 (Accession No. NITE P-1444),
    (e) Lactobacillus brevis (Accession No. FERP BP-4693), and
    (f) Lactococcus lactis subspecies Cremoris CF4 (Accession No. FERM P-20848).
  5. The method of claim 4, wherein
    The lactic acid bacteria culture is a functional sanitary napkin, characterized in that the Lactobacillus plantarum nF1 (Accession Number NITE P-1462) culture.
PCT/KR2017/008163 2016-07-29 2017-07-28 Functional sanitary napkin WO2018021874A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR10-2016-0096967 2016-07-29
KR20160096967 2016-07-29

Publications (1)

Publication Number Publication Date
WO2018021874A1 true WO2018021874A1 (en) 2018-02-01

Family

ID=61017262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/008163 WO2018021874A1 (en) 2016-07-29 2017-07-28 Functional sanitary napkin

Country Status (2)

Country Link
KR (1) KR102087051B1 (en)
WO (1) WO2018021874A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111295B1 (en) 2018-02-05 2020-05-15 주식회사 만도 Apparatus and method for controlling vehicle based on redundant architecture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (en) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
KR20040101335A (en) * 2002-03-21 2004-12-02 비포단 에이/에스 Lactobacillus strains
KR20110010867A (en) * 2009-07-27 2011-02-08 이성기 A hygienic band
KR20140140387A (en) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 Nano-Sized Lactic Acid Bacteria from Kimchi
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940001575B1 (en) * 1991-12-24 1994-02-25 최근선 Disposable absorbent product composition comprising lactoferrin
SE9703669D0 (en) * 1997-10-08 1997-10-08 Moelnlycke Ab And article preparation comprising lactic acid bacteria
SE519648C2 (en) * 1998-03-06 2003-03-25 Essum Ab New strain of Lactobacillus plantarum
SE528382C2 (en) * 2004-10-05 2006-10-31 Probi Ab Probiotic Lactobacillus strains for improved vaginal health

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061201A1 (en) * 1999-04-14 2000-10-19 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products
KR20040101335A (en) * 2002-03-21 2004-12-02 비포단 에이/에스 Lactobacillus strains
KR20110010867A (en) * 2009-07-27 2011-02-08 이성기 A hygienic band
KR20140140387A (en) * 2013-05-29 2014-12-09 바이오제닉스코리아 주식회사 Nano-Sized Lactic Acid Bacteria from Kimchi
US20150209468A1 (en) * 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism

Also Published As

Publication number Publication date
KR20180013793A (en) 2018-02-07
KR102087051B1 (en) 2020-03-10

Similar Documents

Publication Publication Date Title
FI70139C (en) Bakteriedoedande absorptionskropp
EP1255575B2 (en) Foam/film composite medical articles
US5753252A (en) Prevention of toxin production using absorbent products
TW480174B (en) Micro-encapsulated lactobacilli for medical applications
Bowie et al. Differential response of chlamydial and ureaplasma-associated urethritis to sulphafurazole (sulfisoxazole) and aminocyclitols
US5693332A (en) Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
Özçelik et al. Antiviral and antimicrobial activities of three sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis
KR100648559B1 (en) Absorbent Article having a Reduced Viability of Candida Albicans
Lawrence Dressings and wound infection
USRE39892E1 (en) Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
DE69930162T3 (en) Absorbent articles
EP2111833B1 (en) A far-infrared anion compound sanitary napkin and pad
US5641503A (en) Additives to tampons
US6187990B1 (en) Inhibiting the growth of bacteria in absorbent articles by adding other bacteria
Song et al. Dietary clays alleviate diarrhea of weaned pigs
AU2002343596B2 (en) Absorbent article comprising a yucca extract
US6979491B2 (en) Antimicrobial yarn having nanosilver particles and methods for manufacturing the same
ES2301705T3 (en) Hygienic fabric impregnated with a composition that includes a lactic acid producing bacteria suspended in a lipid.
US20100262097A1 (en) Delivery Device
US20040053856A1 (en) Method of producing a tampon capable of inhibiting exoprotein production from gram positive bacteria
EP0395099B1 (en) Additives to tampons
US20010033838A1 (en) Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications &amp; preperations
DE60110380T2 (en) Articles containing milky acid-processing micro-organisms
US7790947B2 (en) Absorbent article
MXPA02000046A (en) Absorbent articles with hydrophilic compositions containing anionic polymers.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17834815

Country of ref document: EP

Kind code of ref document: A1